Life-Saving Role of PSMA PET/CT in Treating Biochemical Recurrence of Prostate Cancer

🎯 The Right Treatment for the Right Patient in Prostate Cancer

Prostate cancer is one of the most common cancers in men, and the high rates of biochemical recurrence (rising PSA values after surgery) pose a significant challenge in clinical management. Approximately 30–40% of patients who undergo radical prostatectomy experience a PSA rise, which is an early indicator of cancer recurrence at the microscopic level.

At this stage, the most effective treatment option is salvage radiotherapy (sRT). However, a critical question arises: How can we predict which patients will truly benefit from this therapy? If the disease has spread microscopically beyond the prostate bed, radiotherapy often leads to unnecessary side effects without providing real benefit.

Conventional imaging methods (CT, MRI, bone scintigraphy) are inadequate in detecting recurrence at low PSA levels. Therefore, most patients undergo sRT without prior imaging. However, this often results in ineffective treatments and unnecessary toxicity for some patients.

A nationwide study conducted in Denmark and published in Journal of Nuclear Medicine in August 2025 revealed that PSMA PET/CT is not only a diagnostic tool but also a method that creates a survival benefit for patients.

💡 These findings strongly indicate that PSMA PET/CT is no longer just a diagnostic tool, but also a game-changing guide in treatment planning.

Design and period: Nationwide, real-world, retrospective cohort conducted between 2015–2023. Data were obtained from Denmark’s national health registries.

Note: PSMA PET/CT had to be performed within 6 months of BCR diagnosis and no later than 6 months before sRT initiation.

Treatment standard: All patients received salvage radiotherapy (sRT) (approximately 30–40 fractions). According to the 2015 guideline update, all patients also received 2 years of ADT (androgen deprivation therapy).

💡 Clinical meaning: Systemic therapy use was similar between groups; the key differentiating factor was more accurate patient and field selection with PSMA.

Baseline characteristics: Groups were similar in age, comorbidities, and pre-surgical parameters. However:

• LN(+) rate was slightly higher in the PSMA group (12.3% vs 9.9%),
• Positive surgical margin rate was lower (50.7% vs 57.5%).

💡 Clinical meaning: Even though the PSMA group had more adverse prognostic factors, outcomes were still better → the key driver was accurate selection with PSMA.

💡 Clinical meaning: Despite the shorter follow-up in the PSMA group, the survival benefit persisted, supporting the robustness of the findings.

Crude hazard ratio (HR): 3.31; p=0.0486
👉 Patients without PSMA had about a 3.3-fold higher risk of death.

Clinical translation:
• The 5-year absolute OS gain of 4.3% is meaningful and clinically valuable.
• Roughly 1 additional life saved for every 23 patients treated (approximate, hypothesis-generating).

HR (for recurrence risk): 1.53; p=0.0187
👉 Patients without PSMA had a 53% higher risk of PSA relapse.

💡 Clinical meaning: PSMA-based patient selection provides strong protection particularly in the early years. While the advantage becomes more modest later, it remains durable.

🧠 Why Does PSMA Provide an Advantage?

• 🎯 Accurate targeting: PSMA PET/CT detects hidden tumor foci outside the prostate bed with high accuracy. This allows radiation fields and doses to be planned in the most precise way.
• 🚫 Avoiding unnecessary treatment: Patients unlikely to benefit are spared unnecessary radiotherapy. This prevents both serious side effects (urinary, bowel) and unnecessary costs.
• ⚡ Early and sensitive intervention: Even when PSA is as low as 0.2–1.0 ng/mL, recurrence sites can be detected with high sensitivity, enabling effective treatment at an earlier stage.

🔎 What Do the Findings Mean?

• 📈 Direct contribution to survival: PSMA PET/CT not only shows recurrence, but also guides the right patient to the right treatment at the right time, improving overall survival.
• 👤 Personalized treatment: Identifies which patients will benefit from radiotherapy and prevents unnecessary treatments.
• 🔬 Higher success with early detection: Performing PSMA PET/CT when PSA is still low helps capture recurrence early and increases treatment success.

🩺 Clinical Message

This study provides strong evidence that PSMA PET/CT should become the “new standard” in planning salvage radiotherapy after biochemical recurrence.

📊 A 5-year absolute overall survival difference of 4.3% (98.1% with PSMA vs 93.8% without) represents a critical, life-impacting gain for patients.